pEntry_HCoV-OC43-nsp9
(Plasmid
#168937)
-
PurposeGateway-compatible Entry vector
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 168937 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepENTR223.1*SfiI
- Backbone size w/o insert (bp) 2800
-
Vector typeGateway-compatible Entry vector
Growth in Bacteria
-
Bacterial Resistance(s)Spectinomycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameHCoV-OC43-nsp9
-
Alt namensp9
-
SpeciesOther
-
Insert Size (bp)330
-
Entrez GeneORF1ab (a.k.a. EYW02_gp1)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site SfiI (unknown if destroyed)
- 3′ cloning site SfiI (unknown if destroyed)
- 5′ sequencing primer M13 uni (-21)
- 3′ sequencing primer M13 rev (-29) (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made bySynthesized by Twist Bioscience
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
5'-linker: SfiI-BamHI-ATG-BamHI (GGCCGTCAaggccaggatccatgggatcc), 3'-linker: PacI-TAA-AsiSI-SfiI (cttaatTAAgacgcgatcgcggcctcatGGGCC).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pEntry_HCoV-OC43-nsp9 was a gift from Pascal Falter-Braun (Addgene plasmid # 168937 ; http://n2t.net/addgene:168937 ; RRID:Addgene_168937) -
For your References section:
A resource of human coronavirus protein-coding sequences in a flexible, multipurpose Gateway Entry clone collection. Weller B, Lin CW, Pogoutse O, Sauer M, Marin-de la Rosa N, Strobel A, Young V, Knapp JJ, Rayhan A, Falter C, Kim DK, Roth FP, Falter-Braun P. G3 (Bethesda). 2023 Jul 5;13(7):jkad105. doi: 10.1093/g3journal/jkad105. 10.1093/g3journal/jkad105 PubMed 37267226